Field Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle Program


Ryan Allway

November 18th, 2020

Psychedelics


Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of technology-enabled psychedelic therapies, announced today that it has entered into a lease and plans to open a Field Trip Health Center in Amsterdam, Netherlands. Located at Piet Heinkade 55 overlooking the IJhaven River, the 665 sqm (7158 sqft) Amsterdam location will be the first Field Trip Health center focused on therapeutic use of psychedelics using legal truffles. Field Trip expects to begin accepting people interested in participating in its truffle programs in December 2020, and the Netherlands location of Field Trip Health is expected to open in March 2021.

“Globally, we are in the midst of a mental health crisis, and The Netherlands is no exception. The prevalence of mental health issues is at all time highs and is being exacerbated by the COVID-19 pandemic. It is estimated that 30% of the Dutch population is experiencing some form of stress-related mental health challenge due to the pandemic,” said Prof. Dr. Jan J.L. Derksen, an advisor to Field Trip in The Netherlands. “Whereas big pharma has fallen short in terms of driving breakthroughs and innovation in mental health, innovative companies like Field Trip are filling the gap. With its truffle-based program embedded in science, therapy and guidance, Field Trip is advancing treatment options with healing psychedelic experiences, while at the same time investing heavily in its own R&D to advance new and exciting molecules to treat mental health issues.”

Studies from institutions such as Johns Hopkins, New York University and Imperial College London have demonstrated that psilocybin therapy, when performed by qualified professionals, can have profoundly positive effects on treating mental and emotional health challenges such as depression, anxiety, end of life distress and addiction. Similar studies have demonstrated that psychedelic therapies may also increase a person’s creativity, empathy, openness to others’ viewpoints and regard for the environment and planet.

“People from around the world have already travelled to The Netherlands to visit retreats providing ceremonial psychedelic experiences with truffles containing psilocybin,” said Onur Yildirim, PhD, Field Trip’s Director of Clinical Operations in The Netherlands. “But in order for these treatments to create the most significant impact and generate broader medical acceptance, they need to be professionalized. And that’s exactly what we are doing with our Field Trip Health Center in Amsterdam. All of our treatment programs with truffles will be administered by accredited and licensed therapists and psychologists and overseen by a licensed psychiatrist to provide the best possible experiences and effects on positive measures of health.”

The Field Trip Health Netherlands location will offer a variety of therapeutic programs using truffles containing psilocybin. Based on the desired experience, the center will offer several program options for individuals as well as couples.

The planned opening of The Netherlands location follows on the announcement in early November of Field Trip’s plans to establish operations in the State of Oregon following the passage of Measure 109 which will effectively create the first legal market for psilocybin therapies in North America.

“An essential part of our strategy is to constantly learn and innovate with all forms of legal psychedelic therapies,” said Ronan Levy, Field Trip’s Executive Chairman. “With this new location, we are going to leverage the experience, data and know-how developed by our clinical staff in our ketamine-enhanced therapy locations in Toronto, New York, Los Angeles and Chicago. We will translate that knowledge-base to the programs being offered in our Field Trip Health Center in Amsterdam. We will then use the collective experience to establish protocols for Oregon and beyond as new psychedelic therapies get legalized and approved.”

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, including psilocybin-producing fungi, and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.fieldtriphealth.nl , https://www.fieldtriphealth.com and https://www.meetfieldtrip.com .

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading